Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. in ESMO open / ESMO Open. 2024 May;9(5):103005. doi: 10.1016/j.esmoop.2024.103005. Epub 2024 Apr 30.

2024
ASL Cuneo 2

Tipo pubblicazione

Review

Autori/Collaboratori (16)Vedi tutti...

Reali A
Radiation Oncology Department, Michele e Pietro Ferrero Hospital, Verduno.
Quaglino P
Department of Medical Sciences, Clinic of Dermatology, University of Turin, Turin.
Peris K
Dermatology, Department of Medicine and Translational Surgery, Università Cattolica del Sacro Cuore, Rome; Dermatology, Department of Medical and Surgery Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome.

et alii...

Abstract

Cutaneous squamous cell carcinoma (CSCC) accounts for ?20%-25% of all skin tumors. Its precise incidence is often challenging to determine due to limited statistics and its incorporation with mucosal forms. While most cases have a favorable prognosis, challenges arise in patients presenting with locally advanced or metastatic forms, mainly appearing in immunocompromised patients, solid organ transplantation recipients, or those facing social difficulties. Traditionally, chemotherapy and targeted therapy were the mainstays for advanced cases, but recent approvals of immunotherapeutic agents like cemiplimab and pembrolizumab have revolutionized treatment options. These guidelines, developed by the Italian Association of Medical Oncologists (AIOM) using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach, aim to guide clinicians in diagnosing, treating, and monitoring patients with CSCC, covering key aspects from primitive tumors to advanced stages, selected by a panel of experts selected by AIOM and other national scientific societies. The incorporation of these guidelines into clinical practice is expected to enhance patient care and address the evolving landscape of CSCC management.

Accesso banca dati bibliografica

PMID : 38688192

DOI : 10.1016/j.esmoop.2024.103005

Keywords

guidelines; cutaneous squamous cell carcinoma; cemiplimab; anti-PD-1; GRADE; CSCC; Practice Guidelines as Topic; Medical Oncology/standards; Italy; Carcinoma, Squamous Cell/therapy/diagnosis; Skin Neoplasms/therapy/diagnosis; Humans; keratinocyte carcinoma; skin cancer;